Research Intelligence & Discovery - software & AI news

Daily news on software, AI, and companies shaping research intelligence & discovery.

Showing 51 results
Press release cover image

Sep 28, 2026

Zifo Unveils AI-Driven Scientific Semantic Layer Vision for Biopharma

New framework aims to turn fragmented scientific data into trusted, evidence-backed intelligence for enterprise AI.Next generation of scientific AI will require more than access to large volumes of data.CAMBRIDGE, Mass. and CAMBRIDGE, England, Sept. 28, 2026 /PRNewswire/ -- Zifo, a global enabler of AI and data-driven enterprise informatics for science-driven organizations, today unveiled its vision for an AI-driven scientific semantic layer, a dynamic framework designed to help Biopharma compan
Press release cover image

Sep 25, 2026

ELEPHAS BIOSCIENCES AND TES PHARMA COLLABORATE TO ADVANCE TRANSLATIONAL RESEARCH FOR LUNG CANCER THERAPY

Tes Pharma Will Use the elive™ Platform to Functionally Evaluate Response to TES-4207 in Live Tumor Fragments as a Monotherapy and in Combination With Immune Checkpoint InhibitorsMADISON, Wis., Sept. 24, 2026 /PRNewswire/ -- Elephas Biosciences Corporation, developer of a functional precision medicine platform for oncology therapy response measurement, today announced a collaboration with Italy-based Tes Pharma to evaluate TES-4207, a first-in-class investigational therapy targeting NR2F6 for tr
Press release cover image

Sep 17, 2026

Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study

The paper introduces three interconnected resources for the global scientific community:LongevityBench, the first open benchmark designed to rigorously evaluate AI reasoning across multiple domains of aging biology;Longevity-LLMs, a family of compact, open-source language models specifically trained on clinical and multi-omics aging data; andLongevity Claw, an open-source agentic research platform that autonomously integrates specialized longevity tools to identify and prioritize potential thera
Press release cover image

Sep 17, 2026

Causaly is Now Available in Microsoft Copilot

Enterprise scientists and knowledge workers can now access Causaly's scientifically grounded research directly inside of Microsoft 365 Copilot, helping users turn evidence into decision-ready intelligenceLONDON, Sept. 17, 2026 /PRNewswire/ -- Causaly today announced an expansion of its collaboration with Microsoft that brings agentic scientific research directly into Microsoft Copilot. Enterprise life sciences R&D can now access Causaly from within their existing Microsoft 365 workflows, inc
Press release cover image

Sep 9, 2026

Two Independent Research Teams Converge on Novel Immune Checkpoint PLA2G2D as a Path to Overcome Anti-PD-1 Resistance in Cancer

Nature publication validates Apeximmune's novel target and reveals an enzyme-independent mechanism the field had overlooked; company's first-in-class anti-PLA2G2D antibody AI-306 advancing toward IND filing in Q2 2027SOUTH SAN FRANCISCO, Calif., Sept. 9, 2026 /PRNewswire/ -- Apeximmune Therapeutics, Inc., an IND-stage immuno-oncology company, today announced the publication of research in Nature validating PLA2G2D as a novel and mechanistically distinct immune checkpoint capable of addressing re
Press release cover image

Aug 27, 2026

ProFound Therapeutics Receives Investment to Tackle Preeclampsia and Eclampsia

Up to $35 million from the Gates Foundation will support ProFound's use of its platform, datasets, and algorithms to identify new drug targets and biomarkers for preeclampsia and eclampsiaCAMBRIDGE, Mass., Aug. 27, 2026 /PRNewswire/ -- ProFound Therapeutics, a Flagship Pioneering company harnessing the expanded human proteome to develop first-in-class medicines for multiple diseases, today announced that it has received an investment commitment of up to $35 million from the Gates Foundation, inc
Press release cover image

Aug 26, 2026

Noetik Achieves First Milestone in Landmark GSK Collaboration

Noetik has met the first near-term milestone under its five-year licensing agreement with GSK, announced in January 2026 with $50M in upfront capital and near-term milestonesAchievement reinforces Noetik's model-licensing approach as a new, recurring-revenue asset class in biotechSAN FRANCISCO--(BUSINESS WIRE)--#GSK--Noetik, an AI company building foundation models of human biology to redefine clinical outcomes in oncology, today announced that it has met the first near-term milestone under its
A minimalist illustration of a pill and a data chart representing pharmaceutical development.

Aug 26, 2026

Centrix and University of Sussex Collaborate to Drive Data-Driven Pharma Development

Centrix Pharma Solutions has joined forces with the University of Sussex to enhance pharmaceutical development through a new Knowledge Transfer Partnership (KTP) that leverages advanced data analytics.This initiative, backed by Innovate UK with a funding of £375,000 ($510,000), aims to merge Centrix's expertise in drug development with the university's data science research. The focus is on creating more reliable methodologies for product development, addressing the challenge of fragmented data
Press release cover image

Aug 26, 2026

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays

SEATTLE and RICHMOND, BC, Aug. 26, 2026 /PRNewswire/ -- Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), today announced a non-exclusive licensing agreement covering Monod Bio's proprietary LuxSit de novo luciferase technology and NovoBodies.Under the terms of the agreement, SignalChem Biotech may incorporate the Monod Bio technologies into custom luminescent assay development and protein
A minimalist representation of a drug compound in flat design.

Aug 25, 2026

After some ‘tough years,’ Frontier’s CEO is ramping up ambitions for precision med platform

Frontier Medicines is navigating a challenging landscape by ramping up its ambitions in precision medicine, focusing on advancing cancer drug candidates while leveraging its AI-driven chemoproteomics platform.The biotech company, having undergone a restructuring that involved layoffs, is now looking ahead with optimism. CEO Chris Varma noted that the difficult decisions made in the past were essential for enhancing operational efficiency and concentrating resources on impactful areas. Despite pr
A mouse model in a petri dish on a lab bench, surrounded by glassware.

Aug 21, 2026

DANDELION Computational Tool Identifies Previously Unknown Asthma-Related Genes and Pathway

Researchers from the University of Chicago and Columbia University have developed a novel computational tool named DANDELION, which identifies genes most directly associated with asthma, significantly advancing the understanding of the disease's genetic underpinnings.The DANDELION tool leverages trans-gene regulation to pinpoint 21 asthma-related genes, many of which were previously unidentified. By utilizing CRISPR gene-editing and mouse models, the team validated that these genes contribute to
Press release cover image

Aug 17, 2026

Cognizant and Benchling Selected as Partners to Accelerate Kyowa Kirin's R&D

Transforming the Research Lifecycle Through Integrated Data Management, Advanced Automation, and AI-Driven WorkflowsTOKYO, Aug. 16, 2026 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) today announced that it will support the introduction and implementation of Benchling, the AI platform for R&D at Tokyo Research Park and Fuji Research Park, research sites in Japan operated by Kyowa Kirin Co., Ltd.Benchling gives scientists a single place to capture structured data, run AI models and agents and auto